The company aims to implement the state of the art technology recombinant protein technology and Hybridoma technology to produce novel proteins, biologicals and antibodies. These products will be available for diagnostic and therapeutic purposes and the company will provide a platform for pharmaceutical, research and biotechnology institutions for the development of biologicals and antibodies